Summary UMN Pharma Inc (UMN Pharma) is a biopharmaceutical company that manufactures therapeutic for muscular dystrophy, diabetes and influenza.The company’s products include UMN-0501, UMN-0502, UMN-2003, UMN-0901 and UMN-2002, among others.
Its UMN-0502 is a seasonal influenza vaccine.UMN Pharma’s UMN-0501 and UMN-0901 are used as pandemic influenza vaccines and others.
The company also provides UMN-2003 product, a norovirus VLP - rotavirus VP6 non-live injectable trivalent vaccine for preventing two major causative agents of acute gastroenteritis in one injection.It also partners with universities and pharmaceutical companies for biosimilars business and biopharmaceuticals manufacturing, among others.
UMN Pharma is headquartered in Yokohama, Japan.
UMN Pharma Inc (4585) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
121 pages •
By Euromonitor International
• Nov 2020
The outbreak of COVID-19 is not set to increase growth in 2020, with value growth of 3% predicted, compared to value growth of 4% recorded in 2019. Unlike other countries within Western Europe, there was not a high level of stockpiling reported for consumer health products in Norway. However, adult acetaminophen was one area which recorded...
122 pages •
By Euromonitor International
• Nov 2020
The outbreak of COVID-19 in South Korea is not predicted to increase growth in 2020, with value growth of 3% expected for the year, compared to value growth of 5% recorded in 2019. As South Korea did not have an enforced lockdown, sales were not impacted by high levels of stockpiling that was seen in other countries Consumer Health...
111 pages •
By Euromonitor International
• Nov 2020
Overall, the COVID-19 pandemic has had a significant negative impact on consumer health sales in China in 2020, as a result of lockdown restrictions on retailing and public movement, and the disruption of logistics and retail operations. Consumer Health in China report offers a comprehensive guide to the size and shape of the market...
The global analytical standards market size is projected to reach USD 1.7 billion by 2025 from USD 1.3 billion in 2020, at a CAGR of 6.3%. Factors such as the increasing adoption of analytical techniques in pesticide monitoring are propelling the growth of the analytical standards market. Additionally, expected patent expiry of major drugs...
Narcolepsy Disease - Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Narcolepsy Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Narcolepsy Clinical trials scenario.This report provides top line data relating to the clinical trials on Narcolepsy. Report...
Central Nervous Systems Therapeutic Drug Monitoring Tests - Medical Devices Pipeline Assessment, 2020 Summary Medical Devices sector report, “Central Nervous Systems Therapeutic Drug Monitoring Tests - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Central...
Global Musculoskeletal Partnering 2014 to 2020 provides the full collection of Musculoskeletal disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Trends in Musculoskeletal partnering deals Financial deal terms for headline, upfront and royalty by stage of development Musculoskeletal...
The Global Antibiotics Partnering Terms and Agreements 2010 to 2020 report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in antibiotics partnering deals Disclosed headlines, upfronts, milestones and royalties...
Head And Neck Cancer - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Head And Neck Cancer - Pipeline Review, H2 2020, provides an overview of the Head And Neck Cancer (Oncology) pipeline landscape. Head and Neck Cancer is a cancer that arises...
Rosacea - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Rosacea - Pipeline Review, H2 2020, provides an overview of the Rosacea (Dermatology) pipeline landscape. Rosacea is a chronic and potentially life-disruptive disorder primarily of the...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.